Key result
Cardiac Safety Simulator tT model accurately predicts quizartinib-induced QTcF prolongation of ~13 ms.
Why the study?
The ability of computational action potential models to predict the clinical QTcF-prolonging effect of the IKs-selective blocker quizartinib was uncertain.
Does the ten Tusscher model better predict the clinical QTcF-prolonging effect of the IKs blocker quizartinib compared to the O'Hara-Rudy model?
Does the ten Tusscher model better predict the clinical QTcF-prolonging effect of the IKs blocker quizartinib compared to the O'Hara-Rudy model?
The ten Tusscher action potential model accurately predicts clinical QTcF prolongation caused by the selective IKs blocker quizartinib, highlighting a sensitivity deficit in the O'Hara-Rudy model for this mechanism.
Answers are grounded in this paper and cite their sources.
tT model predicts quizartinib IKs-mediated QTcF prolongation; extends in silico tools for non-hERG drugs but leaves open prospective validation before wider use.
Quizartinib is a FLT3 kinase inhibitor used in acute myeloid leukaemia (AML). It prolongs QTcF interval in AML patients by inhibiting the slow delayed rectifier potassium current (I Ks ) 1 . This contrasts with the usual I Kr (hERG)-mediated mechanism. We investigated the ability of the ten Tusscher 2006 (tT) and O'Hara-Rudy 2011 (OHR) action potential models to predict the clinical QTcF effect of this I Ks -selective drug. Ion channel data for quizartinib and its metabolite (AC886), along with clinically relevant, unbound concentrations of both entities formed inputs for Cardiac Safety Simulator™ (CSS) software. Quizartinib: I Ks IC 50 0.4 uM; I Kr 16.4% inhibition at 3 uM. AC886: I Ks and I Kr 26.9% and 12.0% inhibition at 3 uM, respectively. Data were analyzed using tT or OHR models, and CSS applied a 1D-string of cells algorithm to generate a pseudo-ECG and thereby calculated QTcF. CSS also simulated the effect of hypokalaemia. Data are median (lower; upper 90% confidence interval). Quizartinib doses of 30 and 60 mg/day increase QTcF in AML patients by 15.9 ms (13.5; 18.4) and 23.7 ms (20.6; 26.2), respectively. Using the unbound C max exposures of quizartinib and AC886 at these doses, tT-based QTcF modelling predicted similar increases: 13.4 ms (10.2; 16.8) and 17.2 ms (14.1; 20.9), respectively. In contrast, OHR-based QTcF modelling did not predict an effect (1.5 ms (0.7; 1.9) and 1.8 ms (1.2; 2.4) using exposures seen at 30 and 60 mg, respectively). Concentration-QTcF modelling of hypokalaemic AML patients ([K + ] < 3.5 mM) indicated a 6.2 ms QTcF baseline increase relative to normokalaemic patients. However, hypokalaemia did not increase the quizartinib effect on QTcF 1 . tT-based QTcF modelling in CSS predicted a similar outcome in hypokalaemic conditions ([K + ] = 3.2 mM): baseline QTcF increased by 7.5 ms (7.2; 8.0); no effect on the quizartinib-induced increase. These data match a previous action potential modelling-based comparison indicating that the tT model is more sensitive than OHR to I Ks inhibition. This indicates the need to enhance the OHR model in terms of its ability to predict the clinical effect of I Ks blockers. 1. Kang D et al. (2021) Cancer Chemother Pharmacol 87 : 513–523.
No takes yet. Share an insight, caveat, or question.
Abbasi et al. (2026) studied Acute myeloid leukaemia (AML). Quizartinib vs. Baseline was evaluated on Predicted QTcF increase at 30 mg/day using tT model (MD 13.4 ms, 95% CI 10.2-16.8). Cardiac Safety Simulator modelling using the ten Tusscher model accurately predicted clinically observed QTcF prolongation with quizartinib, unlike the OHR model.
Synapse has enriched 10 related papers. Consider them for comparative context: